Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging.
MR imaging and (18)F-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.
['Lee|Susanna I|SI|', 'Catalano|Onofrio A|OA|', 'Dehdashti|Farrokh|F|']
D056831:Coordination Complexes D004958:Estradiol D005260:Female D019788:Fluorodeoxyglucose F18 D006801:Humans D008279:Magnetic Resonance Imaging D064847:Multimodal Imaging D009364:Neoplasm Recurrence, Local D009942:Organometallic Compounds D010051:Ovarian Neoplasms D049268:Positron-Emission Tomography D011379:Prognosis D016879:Salvage Therapy D013882:Thiosemicarbazones D014057:Tomography, X-Ray Computed D002583:Uterine Cervical Neoplasms D014594:Uterine Neoplasms
16α-18F-fluoro-17β-estradiol PET Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone) PET diffusion weighted imaging dynamic contrast enhanced MRI perfusion MRI